106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2022 All rights reserved
ASCOGEN02223a
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve
cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/assays-and-predictive-markers-guidelines.
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
assays-and-predictive-markers-guidelines. Copyright © 2022 by American Society of Clinical
Oncolog y. All rights reserved.
Source
Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients with
Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol.
2022 Feb 17. doi:10.1200/JCO.21.02767.
Abbreviations
ATM, ataxia telangiectasia mutated gene; cf DNA, circulating free DNA; CNV, copy
number variation; ctDNA, circulating tumor; CUP, cancers of unknown primary;
dMMR, mismatch repair deficiency; DNA, deoxyribonucleic acid; FDA, Food and Drug
Administration; GIS, genomic instability score; HGVS, Human Genome Variation
Society; HRD, homologous recombination deficiency; ITH, intratumoral heterogeneity;
LOH, loss of heterozygosity; LST, large-scale state transitions; MRD, minimal residual
disease; MSI, microsatellite instability; MSI-H, microsatellite instability-high; NGS, next-
generation sequencing ; NSCLC, non-small cell lung cancer; NTRK, neurotrophic tyrosine
receptor kinase; PARP, poly-ADP ribose polymerase; PCO, provisional clinical opinion;
P/LP, pathogenic or likely pathogenic; RNA, ribonucleic acid; SEGA, subependymal
giant-cell astrocytomas; TAI, telomeric allelic imbalance; TMB, tumor mutation burden;
TMB-H, tumor mutational burden-high; TRK, tyrosine receptor kinase; VAF, variant
allele fraction
